Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 15,825 | PLN 13,201 | PLN 9,158 | PLN 3,986 |
| % Growth | 19.9% | 44.1% | 129.8% | – |
| Cost of Goods Sold | PLN 9,402 | PLN 6,300 | PLN 2,087 | PLN 741 |
| Gross Profit | PLN 6,423 | PLN 6,901 | PLN 7,071 | PLN 3,245 |
| % Margin | 40.6% | 52.3% | 77.2% | 81.4% |
| R&D Expenses | PLN 34,663 | PLN 64,846 | PLN 44,155 | PLN 23,115 |
| G&A Expenses | PLN 4,126 | PLN 16,137 | PLN 19,558 | PLN 19,545 |
| SG&A Expenses | PLN 16,520 | PLN 22,176 | PLN 19,558 | PLN 19,545 |
| Sales & Mktg Exp. | PLN 12,394 | PLN 6,039 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 0 | -PLN 7,105 | -PLN 18,278 | -PLN 7,707 |
| Operating Expenses | PLN 51,183 | PLN 79,917 | PLN 45,435 | PLN 34,953 |
| Operating Income | -PLN 44,760 | -PLN 73,016 | -PLN 38,364 | -PLN 31,708 |
| % Margin | -282.8% | -553.1% | -418.9% | -795.5% |
| Other Income/Exp. Net | PLN 541 | PLN 2,489 | PLN 2,470 | -PLN 863 |
| Pre-Tax Income | -PLN 38,426 | -PLN 70,527 | -PLN 35,894 | -PLN 32,572 |
| Tax Expense | PLN 0 | PLN 57 | PLN 0 | PLN 0 |
| Net Income | -PLN 38,426 | -PLN 70,584 | -PLN 35,894 | -PLN 32,572 |
| % Margin | -242.8% | -534.7% | -391.9% | -817.2% |
| EPS | -8.25 | -15.19 | -8.61 | -7.89 |
| % Growth | 45.7% | -76.4% | -9.1% | – |
| EPS Diluted | -8.25 | -15.19 | -8.61 | -7.89 |
| Weighted Avg Shares Out | 4,660 | 4,646 | 4,168 | 4,128 |
| Weighted Avg Shares Out Dil | 4,660 | 4,646 | 4,168 | 4,128 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 1,044 | PLN 3,083 | PLN 3,127 | PLN 400 |
| Interest Expense | PLN 437 | PLN 323 | PLN 579 | PLN 400 |
| Depreciation & Amortization | PLN 5,059 | PLN 5,440 | PLN 7,094 | PLN 7,355 |
| EBITDA | -PLN 32,930 | -PLN 64,764 | -PLN 28,221 | -PLN 24,410 |
| % Margin | -208.1% | -490.6% | -308.2% | -612.4% |